Drugs · acquisition-cost intelligence
Topiramate
· ingredient topiramate· TOPIRAMATE 200 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$22.71
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other topiramate products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| topiramate | $0.04260 | −$22.66 |
| Topamax | $0.05949 | −$22.65 |
| TOPIRAMATE | $0.30433 | −$22.40 |
| Eprontia | $1.61 | −$21.10 |
| Qsymia | $3.21 | −$19.50 |
| topiramate | $5.66 | −$17.04 |
| Trokendi XR | $9.01 | −$13.70 |
Medicare Part D coverage · CY2026
On 19 plan formularies · typical tier 4
Prior auth 21% · Step therapy 0% · Quantity limit 16% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.